Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors

Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors

BackgroundHepatitis B virus (HBV) reactivation is a common complication in hepatocellular carcinoma (HCC) patients treated with chemotherapy or immunotherapy. This study aimed to evaluate the risk of HBV reactivation and its effect on survival in HCC patients treated with HAIC and lenvatinib plus PD...

Full description

Bibliographic Details
Main Authors: Zhenyun Yang, Renguo Guan, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
HBV reactivation
hepatocellular carcinoma
hepatic arterial infusion chemotherapy
Lenvatinib
programmed cell death receptor-1 inhibitor
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2024.1336619/full

Internet

https://www.frontiersin.org/articles/10.3389/fcimb.2024.1336619/full

Similar Items